Icaritin enhances the antitumor efficacy of irinotecan by dual-targeting carboxylesterase 2 and p53 in vitro and in vivo

Key Points

• Icaritin significantly boosts the antitumor efficacy of irinotecan in vitro and in vivo, leading to improved cancer treatment outcomes.
• The study demonstrates that icaritin targets both carboxylesterase 2 and p53, contributing to enhanced therapeutic effects.
• An in-depth analysis highlights the dual-targeting mechanism involved in the improved efficacy of irinotecan with icaritin.
• These findings indicate a promising combination therapy for enhancing cancer treatment, warranting further investigation.